益肠方联合化疗对结直肠癌术后的治疗作用及对血清中免疫指标的影响  

Effect of Combined Therapy of Tonifying Intestine and Chemotherapy on Postoperative Colorectal Cancer and Immune Index in Serum

作　　者：王子明[1] 赖象权[1] 何本求[1] WANG Ziming;LAI Xiangquan;HE Benqiu(The First Affiliated Hospital of Guiyang College of Traditional Chinese Medicine, Guiyang 550000, Guizhou, Chin)

机构地区：[1]贵阳中医学院第一附属医院肛肠科

出　　处：《中华中医药学刊》2018年第7期1767-1770,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：贵州省科技计划项目子项目[黔科合SY字(2014)3026号]

摘　　要：目的：观察益肠方联合化疗治疗结直肠癌术后的临床治疗效果及其对免疫指标的影响。方法：选取结直肠癌术后患者85例，随机分为对照组及观察组，对照组41例，观察组44例。对照组患者采用XELOX方案治疗，观察组采用益肠方联合XELOX方案治疗。观察比较治疗前后两组患者T细胞的亚群（CD4＋、CD8＋、CD4＋／CD8＋）的比例，及观察两组患者血常规（白细胞数目WBC、红细胞数目RBC），肝功能（谷丙转氨酶ALT、谷草转氨酶AST）的变化；比较治疗后两组卡式评分（KPS评分）、生存质量评分、临床疗效及不良反应。结果：对照组患者的CD4＋／CD8＋明显较治疗前降低（P〈0．05），但观察组患者的CD4＋／CD8＋明显较治疗前升高（P〈0．05），并且治疗后观察组患者血常规指标及肝功能指标明显较对照组的低（P〈0．05）；治疗后观察组的KSP评分变化较对照组更为明显（P〈0．05），观察组患者生存质量评分的功能领域、症状领域及其他均明显优于对照组（P〈0．05）。观察组的临床疗效明显优于对照组（P〈0．05），不良反应明显少于对照组（P〉0．05）。结论：益肠方联合化疗治疗结直肠癌具有良好的临床疗效，不良反应少，值得在临床上推广。Objective： To observe the clinical effect and influence of immunity therapy on the treatment of colorectal cancer with combined therapy of tonifying intestine and chemotherapy. Methods： Eighty-five cases of postoperative colorectal cancer patients were randomly divided into the control group and the observation group： 41 cases in the control group,44 cases in the observation group. Patients in the control group were treated with XELOX regimen,and the observation group was treated with the combination of Benefiting Intestine Recipe and XELOX regimen. Before and after treatment,we observed 2 groups＇ T cell subsets（ CD4＋,CD8＋,CD4＋/CD8＋） and the proportion of blood（ WBC,RBC）,liver function（ ALT and AST ALT AST） changes. And we compared the KPS score,quality of life score,clinical efficacy and adverse reactions. Results： After treatment,the observation group＇s blood routine indexes and liver function index were significantly lower compared with those of the control group（ P〈 0. 05）. The control group＇s CD4＋/CD8＋ was significantly lower after treatment（ P〈 0. 05）,but the observation group＇s CD4＋/CD8＋ was significantly higher after treatment（ P〈 0. 05）. After treatment,the changes of KSP score in the observation group were superior to those in control group（ P〈 0. 05）. The field of functional areas,quality of life score and the other symptoms in the observation group were significantly better than those of the control group（ P〈 0. 05）. The clinical efficacy of the observation group was significantly better than that of the control group,and the adverse reactions were significantly less than that of the control group（ P 〉0. 05）. Conclusion： It has good clinical efficacy in the treatment of colorectal cancer with the combination of tonifying the bowel and chemotherapy. It is worthy of clinical promotion.

关 键 词：化疗 益肠方 CD4^+/CD8^+ 生活质量 

分 类 号：R735.37[医药卫生—肿瘤]